Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
eNq1mFFv2jAQx9/5FFHeSQgtpZsC1cbaDalVGS3atJfKJEcxc+30bAPdp59D6EYnR10Nfozt/O/sO//u5PRs/cCCJaCkgvfCJGqFAfBM5JTf98LJ7UXzNDzrN9IFWZKdZd2oFSXtMMgYkbIXlrPRFAiX0fery09g/gcM+40gFdMFZOrFOq0oi74QOb8iRbkmSJeC5sEDqLnIe2Gh1WY0SKVC40V/JfCnLEgGabwd2Z1d3B3vjqdxKfYfqloCXhJ+bxUF7qSZaUTgakAU3At8qvH3yEmbyjFIoTGDEVHzEYolzSG3mpgRJsHJyGyV3wAuGajSiFU8XmQP0kmcLMh6DI9Du9MfzOxArVWz1Uy6nePOcXLabbePTpxM4c5R2aNgNhFnd0m33Ura3Rh4zHRmQkelY3BGAhVhnsJC5eBlZnmyg/D4avhzKgtGnqKFLFyPiiAx04Dm/vvbSLmDWzREYubM/tHnmrH4jV5Ptrzw5HGJo4HQXNVg42LsehADwRWs6yPqRjq13uYiBXk42V+C2yk/0lNGM1emGepokGoyHtYj7aA0+EgkTNAfDr5RnouVPDxmdsPqyftiQ0qraIF5ctd+d3qSdDrOt+iHyaGaGnOuURQQGwA5RnbLlSGfiX2JYtLSLvWclIfLx02rIzLCoKbZaTrSxSTic2/mLdX9XaNqwir6+fzWNT++asCnm82nVZrmvT+RdUOvD56bbKx1/O25XV1xL22wRjs65koV8n0cr1araE5kUxJzStEMD8/2nXrqrwv3UrSrJqbioyfXp1Xhe1uIXK/aa2V931Z1+/+2JbbaUKhhj1hUVPbGzuH54XH8t0/15vboBT78mdn0lERRwX21OnpqVdyvAJi48gs0gLiezWjNq0htXqZx9SLTb6Rx+RrTb/wGGtnmYQ==
f9mszeG9q2RSrtqE
Listen
